Neoadjuvant versus adjuvant radiotherapy for centrally located hepatocellular carcinoma: a propensity score matching study based on two prospective phase II trials
Neo-IMRT plus surgery was as effective and safe as surgery plus Adj-IMRT for patients with cl-HCC. Further prospective trials are warranted to confirm the findings.
Authors
- Yuan Tang
- Jing Jin (ORCID: https://orcid.org/0000-0003-3478-1610)
- Yueping Liu (ORCID: https://orcid.org/0000-0002-4582-114X)
- Ye‐Xiong Li (ORCID: https://orcid.org/0000-0003-0985-235X)
- Jianxiong Wu (ORCID: https://orcid.org/0000-0003-2129-9032)
- Fan Wu (ORCID: https://orcid.org/0000-0001-7686-2887)
- Dezuo Dong (ORCID: https://orcid.org/0000-0001-6008-7193)
- Hongzhi Wang (ORCID: https://orcid.org/0000-0003-3608-8932)
- Bo Chen (ORCID: https://orcid.org/0000-0003-3383-3992)
- Liming Wang (ORCID: https://orcid.org/0000-0002-3128-2747)
- Hui Fang (ORCID: https://orcid.org/0000-0003-3509-1486)
- Weihu Wang (ORCID: https://orcid.org/0000-0003-4969-398X)
- Weiqi Rong
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251342686
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Beijing Municipal Science and Technology Commission